Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC
30:09
30:09
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:09Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214
23:28
23:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
23:28Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update
30:03
30:03
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:03Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer
25:28
25:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
25:28Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
27:07
27:07
나중에 재생
나중에 재생
리스트
좋아요
좋아요
27:07Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes
28:23
28:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
28:23Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
…
continue reading
Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
…
continue reading
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
…
continue reading
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC
33:11
33:11
나중에 재생
나중에 재생
리스트
좋아요
좋아요
33:11David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
…
continue reading
残念ながらNegative StudyとなったTROPICs-04についてUromigosJapanの3人が忖度なしに、その原因や理由について考察をします!!
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
40:05
40:05
나중에 재생
나중에 재생
리스트
좋아요
좋아요
40:05Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.
…
continue reading
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
…
continue reading
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待!
…
continue reading
Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer
…
continue reading
David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
…
continue reading
Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
…
continue reading
Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.
…
continue reading
Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
…
continue reading
JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです
…
continue reading
Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.
…
continue reading
Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 370: Artificial Intelligence in Medical Oncology
44:46
44:46
나중에 재생
나중에 재생
리스트
좋아요
좋아요
44:46Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology
…
continue reading
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
…
continue reading
Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer
56:48
56:48
나중에 재생
나중에 재생
리스트
좋아요
좋아요
56:48Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 366: ARPIs in Prostate Cancer - Are They Different?
31:51
31:51
나중에 재생
나중에 재생
리스트
좋아요
좋아요
31:51Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)
47:59
47:59
나중에 재생
나중에 재생
리스트
좋아요
좋아요
47:59Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.
…
continue reading
腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
14:23
14:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
14:23前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
…
continue reading
膀胱がんの最新の話題〜周術期薬物療法とADC〜
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
25:43
25:43
나중에 재생
나중에 재생
리스트
좋아요
좋아요
25:43Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
…
continue reading
Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
…
continue reading
The RCC panel at Uromigos Live 2024 discusses and debates this topic.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville
21:59
21:59
나중에 재생
나중에 재생
리스트
좋아요
좋아요
21:59Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
1:03:10
1:03:10
나중에 재생
나중에 재생
리스트
좋아요
좋아요
1:03:10Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC
26:22
26:22
나중에 재생
나중에 재생
리스트
좋아요
좋아요
26:22Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 355: #UromigosLive24 - Radioligands in prostate cancer
54:23
54:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
54:23The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer
44:00
44:00
나중에 재생
나중에 재생
리스트
좋아요
좋아요
44:00Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
…
continue reading
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
…
continue reading
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
…
continue reading
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
…
continue reading
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
…
continue reading
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
…
continue reading
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
17:59
17:59
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:59Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC
25:47
25:47
나중에 재생
나중에 재생
리스트
좋아요
좋아요
25:47Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
31:10
31:10
나중에 재생
나중에 재생
리스트
좋아요
좋아요
31:10Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC
22:32
22:32
나중에 재생
나중에 재생
리스트
좋아요
좋아요
22:32Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
…
continue reading
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
…
continue reading